Screener Summaries Updates Institutions Sign In More Updates › Other Events › AIM Other Events · Jun 10, 2026
On June 9, 2026, AIM ImmunoTech Inc. Board of Directors approved and adopted an Amendment to the Company's Amended and… AIM AIM ImmunoTech Inc.
On June 9, 2026, AIM ImmunoTech Inc. Board of Directors approved and adopted an Amendment to the Company's Amended and Restated Bylaws, changing the voting standard for proposals other than director elections to a majority of the votes cast on the proposal. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-oncology therapies.
More from AIM ImmunoTech Inc. AIM ImmunoTech releases investor presentation highlighting Ampligen opportunity in pancreatic cancer Nov 5, 2026 AIM ImmunoTech converts $400K of promissory notes into 1.75M shares at $0.228 per share Sep 14, 2026 AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000… Sep 10, 2026 AIM ImmunoTech Inc. converted approximately $1,224,341 of outstanding debt under a Promissory Note dated February 16… Sep 4, 2026 AIM ImmunoTech Inc. received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained… Jun 15, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
